{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:50:34Z","timestamp":1782935434607,"version":"3.54.5"},"reference-count":159,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/13543776.2026.2676080","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:23:03Z","timestamp":1778948583000},"page":"643-664","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["An updated patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2020\u20132025)"],"prefix":"10.1080","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-2545","authenticated-orcid":false,"given":"Sida","family":"Shen","sequence":"first","affiliation":[{"name":"Vanqua Bio","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"e_1_3_3_3_1","unstructured":"U.S. Food & drug administration [Internet]. (WA) (DC): United States Govenment; [cited 2026 Feb 21]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph3092751"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0773-9"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2018.1459568"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2019.1708901"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-022-02987-8"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.4c00031"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2024.2404571"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2140"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/146493"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.9b00934"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2134"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0854.2012.01347.x"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2018.1541235"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1835"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M802786200"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00184"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02258-0"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.236711"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266310"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302778"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091280"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42237-3"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00946"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00567"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja0341440"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja102758v"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00560"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201500486"},{"key":"e_1_3_3_32_1","unstructured":"U.S. Food & Drug Administration [Internet]. (WA) (DC): United States Govenment; [cited 2026 Feb 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217865Orig1s000IntegratedR.pdf"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112887"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00853"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1223"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94923-w"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-021-00515-3"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.3c00212"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01269"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01345"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115885"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01677"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387365"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13738"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000001114"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0238"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4652"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.14348\/molcells.2022.5005"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2022-0157"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93232-6"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13081"},{"key":"e_1_3_3_52_1","unstructured":"Biopharma Dealmakers [Internet]. (NY) (NY): Springer Nature; [cited 2026 Feb 21]. Available from: https:\/\/www.nature.com\/articles\/d43747-022-00165-8"},{"key":"e_1_3_3_53_1","unstructured":"PNS 2022 annual meeting elibrary [Internet]. Miami (FL): Peripheral nerve society; [cited 2026 Feb 21]. Available from: https:\/\/elibrary.pnsociety.com\/pns\/2022\/eposters\/356919\/ka.young.hong.ckd-510.a.novel.selective.hdac6.inhibitor.is.well-tolerated.and.html?f=listing%3D4%2Abrowseby%3D8%2Asortby%3D2%2Aspeaker%3D906734%2Alabel%3D24421"},{"key":"e_1_3_3_54_1","unstructured":"Korea biomedical review [Internet]. Seoul South Korea: The Korean Doctors\u2019 Weekly; [cited 2026 Feb 21]. Available from: https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=13719"},{"key":"e_1_3_3_55_1","unstructured":"Seoul economic daily [Internet]. Seoul South Korea: Seoul Economic Daily Co; [cited 2026 Feb 21]. Available from: https:\/\/en.sedaily.com\/culture\/2026\/01\/20\/korean-pharma-companies-to-unveil-key-clinical-trial"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp3687"},{"key":"e_1_3_3_57_1","unstructured":"Avstera Therapeutics [Internet]. Malvern (PA): Avstera Therapeutics; [cited 2026 Feb 21]. Available from: https:\/\/avstera.com\/wp-content\/uploads\/2023\/12\/Avstera-Therapeutics-Announces-FDA-Clearance-of-IND-Application-for-AVS100.pdf"},{"key":"e_1_3_3_58_1","unstructured":"Tenaya Therapeutics [Internet]. San Francisco (CA): Tenaya Therapeutics; [cited 2026 Feb 21]. Available from: https:\/\/investors.tenayatherapeutics.com\/news-releases\/news-release-details\/tenaya-therapeutics-presents-encouraging-new-clinical-and\/#:~:text=Phase%201%20clinical%20trial%20results%20for%20TN%2D301 starting%20at%20approximately%2025%20mg%20and%20higher"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.10.426"},{"key":"e_1_3_3_60_1","unstructured":"Augustine Therapeutics [Internet]. Leuven Belgium: Augustine Therapeutics; [cited 2026 Feb 21]. Available from: https:\/\/www.augustinetx.com\/media\/augustine-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-evaluating-lead-candidate-agt-100216-for-the-treatment-of-charcot-marie-tooth-disease"},{"key":"e_1_3_3_61_1","unstructured":"Lee J Kim Y Lee Chang SIK et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. 1 3 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor and the pharmaceutical composition comprising the same. WO patent WO 2017\/023133. 2016 p. A2."},{"key":"e_1_3_3_62_1","unstructured":"Ha N Bae Dae K Kim Min C et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Compositions for preventing or treating charcot-marie-tooth disease (CMT). WO patent WO 2023\/031775. 2022 p. A1."},{"key":"e_1_3_3_63_1","unstructured":"Lee Ju HEE Lee Beom S Kang J. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Compositions for preventing or treating pulmonary arterial hypertension. WO patent WO 2023\/144736 A1. 2023."},{"key":"e_1_3_3_64_1","unstructured":"Lee Ju HEE Lee Beom S Jang Yeong SU. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Compositions for preventing or treating heart failure (hf). WO patent WO 2023\/144737 A1. 2023."},{"key":"e_1_3_3_65_1","unstructured":"Ha N Kim Min C Lee Suk JIN et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Compositions for preventing or treating idiopathic pulmonary fibrosis (IPF). WO patent WO 2023\/223174. 2023 p. A1."},{"key":"e_1_3_3_66_1","unstructured":"Lee Ju HEE Lee Beom S Jang Yeong SU et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Compositions for preventing and treating renal failure (RF). WO patent WO 2024\/141925 A1. 2023."},{"key":"e_1_3_3_67_1","unstructured":"Eom D Park J Kim Dong W et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. New preparation method of compound and new crystalline form. WO patent WO 2025\/003974. 2024 p. A1."},{"key":"e_1_3_3_68_1","unstructured":"Lee J Oh Jung T Song H et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Oxadiazole derivative compounds and the pharmaceutical composition comprising the same. WO patent WO 2024\/180464 A1. 2024."},{"key":"e_1_3_3_69_1","unstructured":"Lee Chang SIK Oh Jung T Song H et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. 1 3 4-oxadiazole thiocarbonyl compounds as histone deacetylase 6 inhibitor and pharmaceutical composition comprising the same. WO patent WO 2022\/215020 A1. 2022."},{"key":"e_1_3_3_70_1","unstructured":"Lee Chang KON Ko Moo S Yun Seok H et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. 1 3 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor and the pharmaceutical composition comprising the same. WO patent WO 2021\/210857 A1. 2021."},{"key":"e_1_3_3_71_1","unstructured":"Lee Chang SIK Oh Jung T Yun H et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. 1 3 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor and the pharmaceutical composition comprising the same. WO patent WO 2020\/240492 A1. 2020."},{"key":"e_1_3_3_72_1","unstructured":"Lee Chang SIK Oh Jung T Song H et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. 1 3 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor and uses thereof. WO patent WO 2023\/195809A1. 2023."},{"key":"e_1_3_3_73_1","unstructured":"Oh Jung T Song H Lee Chang SIK. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Sulfoximine compounds as histone deacetylase 6 inhibitor and pharmaceutical composition comprising the same. WO patent WO 2024\/079682 A1. 2023."},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114501"},{"key":"e_1_3_3_75_1","unstructured":"Lee Chang KON Ko Moo S Gwak D-Y et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. 1 3 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor and the pharmaceutical composition comprising the same. WO patent WO 2021\/172886 A1. 2021."},{"key":"e_1_3_3_76_1","unstructured":"Lee Chang KON Ko Moo S Yun Seok H et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. 1 3 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor and the pharmaceutical composition comprising the same. WO patent WO 2021\/172887 A1. 2021."},{"key":"e_1_3_3_77_1","unstructured":"Lee Chang SIK Oh Jung T Yun H et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. 1 3 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor and pharmaceutical composition comprising the same. WO patent WO 2020\/022794 A1. 2019 Jul 25."},{"key":"e_1_3_3_78_1","unstructured":"Lee Jae K Min J In Jin K et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Novel compounds as histone deacetylase 6 inhibitor and pharmaceutical composition comprising the same. WO patent WO 2022\/013728 A1. 2021 Jul 13."},{"key":"e_1_3_3_79_1","unstructured":"Lee Jae K Min J In J et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. 1 3 4-oxadiazole triazole compounds as histone deacetylase 6 inhibitor and pharmaceutical composition comprising the same. WO patent WO 2024\/013690 A1. 2023 Jul 13."},{"key":"e_1_3_3_80_1","unstructured":"Lee Jae K Min J In J et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. 1 3 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor and uses thereof. WO patent WO 2024\/054071 A1. 2023 Sep 07."},{"key":"e_1_3_3_81_1","unstructured":"Lee Chang SIK Oh Jung T Yun H et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Novel compounds as histone deacetylase 6 inhibitor and pharmaceutical composition comprising the same. WO patent WO 2022\/049496 A1. 2021 Sep 01."},{"key":"e_1_3_3_82_1","unstructured":"Lee Chang SIK Oh Jung T Yun H et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. 1 3 4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor and the pharmaceutical composition comprising the same. WO patent WO 2020\/240493 A1. 2020 May 29."},{"key":"e_1_3_3_83_1","unstructured":"Ito M Sugiyama H Yamamoto T et al. Inventors; Takeda Pharmaceuticals Co. assignee. 2-isoindol-1 3 4-oxadiazole derivatives useful as HDAC6 inhibitors. WO patent WO 2021\/060567 A1. 2020 Sep 24."},{"key":"e_1_3_3_84_1","unstructured":"Ito M Yamamoto T Kakegawa K et al. Inventors; Takeda Pharmaceuticals Co. assignee. Heterocyclic compound. JP patent JP WO2020158762 A1. 2020 Jan 29."},{"key":"e_1_3_3_85_1","unstructured":"Zhang G Wang K Li J et al. Inventors; Suzhou Genhouse Bio Co. Ltd. assignee. Oxadiazole compound pharmaceutical composition comprising same and use thereof. WO patent WO 2023\/198172 A1. 2023 Apr 14."},{"key":"e_1_3_3_86_1","unstructured":"Zhang G Zuo G Cui J et al. Inventors; Suzhou Genhouse Bio Co. Ltd. assignee. Crystalline form of HDAC6 inhibitor and preparation method therefor. WO patent WO 2025\/067416 A1. 2024 Sep 27."},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.8b00600"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0688-5"},{"key":"e_1_3_3_89_1","unstructured":"Vara Salazar Yosu ION Aldaba Ar\u00e9valo E Bello Iglesias T et al. Inventors; quimatryx S.L. \/ fund kertor assignee. 1 3 4-oxadiazole derivatives as histone deacetylase inhibitors. WO patent WO 2020\/212479 A1. 2020 Apr 16."},{"key":"e_1_3_3_90_1","unstructured":"Piscopio A Zhang GAN Hunt K. Inventors; Onkure Inc. assignee. Benzimidazole compounds as HDAC6 inhibitors. WO patent WO 2021\/133957 A1. 2020 Dec 23."},{"key":"e_1_3_3_91_1","unstructured":"Villagra A Kozikowski A Tueckmantel W. Inventors; Georgetown University assignee. A1h-benzo[c][2]thiadiazine-2 2-dioxides bearing heterocyclic linkers as selective histone deacetylase 6 inhibitors. WO patent WO 2023\/154758 A1. 2023 Feb 08."},{"key":"e_1_3_3_92_1","unstructured":"Wagner F Yates C Richardson T. inventors; Eikonizo Therapeutics Inc. assignee. Inhibiting histone deacetylase 6 (HDAC6). WO patent WO 2023\/196605 A1. 2023."},{"key":"e_1_3_3_93_1","unstructured":"Wagner F Richardson TOM. Inventors; Eikonizo Therapeutics Inc. assignee. Oxadiazole HDAC6 inhibitors and uses thereof. WO patent WO 2023\/196601 A1. 2023 Apr 07."},{"key":"e_1_3_3_94_1","unstructured":"Marchini M Vergani B Sandrone G et al. inventors; Italfarmaco SPA assignee. 2-(4-((5-(Benzo[B]thiophen-3-yl)-1h-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1 3 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC6) for use in treating e.g. peripheral neuropathy. WO patent WO 2022\/029041 A1. 2021 Jul 30."},{"key":"e_1_3_3_95_1","unstructured":"Marchini M Vergani B Steinkuhler C et al. Inventors; Italfarmaco SPA assignee. 1 3 4-oxadiazole derivatives as selective histone deacetylase 6 inhibitors [1 2]. WO patent WO 2024\/017897 A1. 2023."},{"key":"e_1_3_3_96_1","unstructured":"Marchini M Vergani B Cellupica E et al. Inventors; Italfarmaco SPA assignee. Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors. WO patent WO 2024\/033293. 2023 p. A1."},{"key":"e_1_3_3_97_1","unstructured":"Mandegar Mohammad A Patel S Ding P et al. Inventors; Tenaya Therapeutics Inc. assignee. Fluoroalkyl-oxadiazoles and uses thereof. WO patent WO 2021\/127643 A1. 2020."},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl5654"},{"key":"e_1_3_3_99_1","unstructured":"Mandegar Mohammad A Yang JIN Hoey Timothy C. Inventors; Tenaya Therapeutics Inc. assignee. HDAC6 inhibitors for use in the treatment of dilated cardiomyopathy. WO patent WO 2022\/226388 A1. 2022 Apr 22."},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45440-7"},{"key":"e_1_3_3_101_1","unstructured":"Yang JIN Mandegar Mohammad A Hoey Timothy C. Inventors; Tenaya Therapeutics Inc. assignee. 2-fluoroalkyl-1 3 4-oxadiazol-5-yl-thiazol HDAC6 inhibitors for use in the treatment of metabolic disease and HFpEF. WO patent WO 2022\/235842 A1. 2022 May 04."},{"key":"e_1_3_3_102_1","unstructured":"Jing Frank Y Leong J Lim Beatriz J et al. Inventors; Tenaya Therapeutics Inc. assignee. Compounds for improvement of viral production. WO patent WO 2024\/081927 A1. 2024."},{"key":"e_1_3_3_103_1","unstructured":"Hoey Timothy C Argast Gretchen M Tingley Whittemore G. Inventors; Tenaya Therapeutics Inc. assignee. HDAC6-selective inhibitor for use in the treatment of obesity cardiovascular and metabolic diseases and disorders. WO patent WO 2025\/076457 A1. 2024 Oct 04."},{"key":"e_1_3_3_104_1","unstructured":"Carceller Gonz\u00e1lez E Ortega Mu\u00f1oz A Salas Solana J. Inventors; Oryzon Genomics SA assignee. 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1 2 4-oxadiazole derivatives as HDAC6 inhibitors. WO patent WO 2020\/245381. 2020 Jun 05 p. A1."},{"key":"e_1_3_3_105_1","unstructured":"Packiarajan M Lee PIL White A et al. Inventors; University of Michigan assignee. Non-hydroxamate HDAC6 inhibitors and related methods of use. WO patent WO 2022\/197690 A1. 2022."},{"key":"e_1_3_3_106_1","unstructured":"Raimundo B. Inventor; Valo Health Inc. assignee. Histone deacetylase 6 inhibitor compounds and uses thereof. WO patent WO 2023\/081328 A1. 2022 Nov 04."},{"key":"e_1_3_3_107_1","unstructured":"Celanire S Dos Santos Carvalho Joao F Rombouts Frederik Jan R et al. Inventors; Augustine Therapeutics assignee. Compounds and use thereof as hdac6 inhibitors. WO patent WO 2023\/118507 A3. 2022."},{"key":"e_1_3_3_108_1","unstructured":"Celanire S Rombouts Frederik Jan R Sennhenn Peter C. Inventors; Augustine Therapeutics assignee. Heteroaryl-amine compounds and use thereof as HDAC6 inhibitors. WO patent WO 2024\/261329 A1. 2024 Jun 21."},{"key":"e_1_3_3_109_1","unstructured":"Celanire S Rombouts Frederik Jan R. Inventors; Augustine Therapeutics assignee. Amide-amine compounds and use thereof as HDAC6 inhibitors. WO patent WO 2024\/261328 A1. 2024 Jun 21."},{"key":"e_1_3_3_110_1","unstructured":"Celanire S Rombouts Frederik Jan R. Inventors; Augustine Therapeutics assignee. 2-(heteroaryl-thio)-1-(heteroaryl)ethanone compounds and use thereof as HDAC6 inhibitors. WO patent WO 2024\/261327 A1. 2024 Jun 21."},{"key":"e_1_3_3_111_1","unstructured":"Letai A Ni Chonghaile T Dowling C et al. Inventors; Royal college of surgeons in Ireland assignee. Selective HDAC6 inhibitor. WO patent WO 2022\/129256 A1. 2021 Dec 15."},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc4897"},{"key":"e_1_3_3_113_1","unstructured":"Hase K Takahashi D Suzuki T et al. Inventors; Keio university Osaka university Fujifilm Corp. assignee. Agent for treating inflammatory bowel disease and amide compound or salt thereof. WO patent WO 2021\/201120 A1. 2021 Mar 31."},{"key":"e_1_3_3_114_1","unstructured":"Ueda S Tamura T Terada D et al. Inventors; Fujifilm Corp. assignee. Amide compound or salt thereof pharmaceutical composition and histone deacetylase inhibitor. WO patent WO 2021\/201126 A1. 2021 Mar 31."},{"key":"e_1_3_3_115_1","unstructured":"Baker D Salveson P Moyer A. Inventors; University of Washington assignee. Potent and selective HDAC6 macrocyclic inhibitors. WO patent WO 2023\/205188 A1. 2023."},{"key":"e_1_3_3_116_1","unstructured":"Lee C Yang H-M Choi H et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Novel compounds for selective histone deacetylase inhibitors and pharmaceutical composition comprising the same. WO patent WO 2014\/178606 A1. 2014."},{"key":"e_1_3_3_117_1","unstructured":"Choi Young IL Ha N Bae D et al. inventors; Chong Kun Dang Pharmaceutical Corp. assignee. Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate. WO patent WO 2020\/076129 A1. 2019."},{"key":"e_1_3_3_118_1","unstructured":"Choi Young IL Ha N Suh Dong H. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Compositions for preventing or treating chronic obstructive pulmonary diseases (COPD). WO patent WO 2021\/079300 A1. 2020 Oct 22."},{"key":"e_1_3_3_119_1","unstructured":"Ha N Bae Dae K Kim Min C et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Composition for preventing or treating multiple sclerosis. WO patent WO 2022\/203429. 2022 Mar 24 p. A1."},{"key":"e_1_3_3_120_1","unstructured":"Ha N Kim Min C Bae Dae K et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Compositions for preventing or treating idiopathic pulmonary fibrosis (IPF). WO patent WO 2023\/073600. 2022 Oct 27 p. A1."},{"key":"e_1_3_3_121_1","unstructured":"Song H Lee C Kwak D et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same. WO patent WO 2015\/137750. 2015 Mar 12. p. A1."},{"key":"e_1_3_3_122_1","unstructured":"Choi Young IL Ha N Ju Y S et al. Inventors; Chong Kun Dang pharmaceutical Corp. assignee. Pharmaceutical composition comprising histone deacetylase 6 inhibitors. WO patent WO 2020\/106119. 2019 Nov 22. p. A1."},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15231"},{"key":"e_1_3_3_124_1","unstructured":"Gunning Patrick T Olaoye O Toutah K et al. Inventors; 2681603 Ontario Inc. assignee. Halogenated phenylsulfonamide hydroxamic acid compounds compositions and uses thereof as selective HDAC6 inhibitors. WO patent WO 2020\/194272 A1. 2020 Mar 27."},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01585"},{"key":"e_1_3_3_126_1","unstructured":"Gunning P Olaoye O Nawar N. Inventors; the governing council of the University of Toronto assignee. Histone deacetylase inhibitors and use of the same. WO patent WO 2024\/028654 A2. 2023."},{"key":"e_1_3_3_127_1","unstructured":"Wu HAO Wei C Guo Q et al. Inventors; Medshine discovery Inc. assignee. HDAC6 selective inhibitors preparation method therefor and application thereof. WO patent WO 2018\/130155 A1. 2018 Jan 10."},{"key":"e_1_3_3_128_1","unstructured":"Guo Q Wei C Xiao YAO et al. Inventors; Cstone Pharmaceuticals assignee. Polymorph of hdac6-selective inhibitor and application thereof. WO patent WO 2020\/007329 A1. 2019 Jul 03."},{"key":"e_1_3_3_129_1","unstructured":"Li Z Li FU Ren Z. Inventors; Cstone Pharmaceuticals (Suzhou) Co. Ltd. assignee. HDAC6 selective inhibitor and combination therapy thereof. WO patent WO 2021\/110121 A1. 2020."},{"key":"e_1_3_3_130_1","unstructured":"Barreiro G Sant\u2019ana Danilo Pereira DE Monteiro J\u00falia L et al. Inventors; Eurofarma Laborat\u00f3rios S.A. \/ Federal University of Rio de Janeiro (UFRJ) assignee. Selective HDAC6-inhibiting N-acylhydrazone compounds methods for producing same compositions uses treatment methods and kits. WO patent WO 2023\/097386 A1. 2022 Dec 01."},{"key":"e_1_3_3_131_1","unstructured":"Li J Guo Z Zhang Q et al. Inventors; Shanghai Zhongze Therapeutics Co. Ltd. \/ Shanghai institute of pharmaceutical industry assignee. Benzonitric heterocyclic compound preparation method therefor and use thereof. WO patent WO 2021\/208945. 2021 Apr 14 p. A1."},{"key":"e_1_3_3_132_1","unstructured":"Zhang G Li J Wang K et al. Inventors; Suzhou Genhouse Bio Co. Ltd. assignee. Benzo-condensed ring compound pharmaceutical composition comprising same preparation method therefor and use thereof. WO patent WO 2022\/222856 A1. 2022 Apr 15."},{"key":"e_1_3_3_133_1","unstructured":"Li J Wang K. Inventors; Suzhou Genhouse Bio Co. Ltd. assignee. Tricyclic compound pharmaceutical composition comprising same and use thereof. WO patent WO 2023\/020416 A1. 2022 Aug 15."},{"key":"e_1_3_3_134_1","unstructured":"Shapiro G Tueckmantel W. Inventors; Miralinc pharma Inc. assignee. Heterocyclic compounds as selective HDAC6 inhibitors. WO patent WO 2024\/192237 A1. 2024 Mar 14."},{"key":"e_1_3_3_135_1","unstructured":"Yu C-W Chern J-W. Inventors; Gilva Therapeutics CO Ltd. assignee. Quinazolinone derivatives for HDAC inhibition. WO patent WO 2025\/085669. 2024 Oct 17 p. A1."},{"key":"e_1_3_3_136_1","unstructured":"Wagner F Hooker J Ouellet S. Inventors; Eikonizo Therapeutics Inc. assignee. HDAC6 inhibitors and uses thereof. WO patent WO 2021\/021979. 2020 Jul 30 p. A2."},{"key":"e_1_3_3_137_1","unstructured":"Wagner F. Inventor; Eikonizo Therapeutics Inc. assignee. HDAC6 inhibitors and uses thereof. WO patent WO 2022\/169985. 2022 Feb 03 p. A4."},{"key":"e_1_3_3_138_1","unstructured":"Wagner F Hickman D. Inventors; Eikonizo Therapeutics Inc. assignee. HDAC6 inhibitors and uses thereof. WO patent WO 2023\/150203. 2023 Feb 02 p. A1."},{"key":"e_1_3_3_139_1","unstructured":"Jeon R Mishra Chandra B Kim J. Inventors; Sookmyung Women\u2019s University industry-Academic cooperation Foundation assignee. Novel heterocyclic inhibitor for histone deacetylase and pharmaceutical composition comprising same. WO patent WO 2023\/177250 A1. 2023 Mar 17."},{"key":"e_1_3_3_140_1","unstructured":"Jeon R Cho H Yoon Hye JI et al. Inventors; Sookmyung Women\u2019s University industry-Academic cooperation Foundation assignee. Quinoline-based histone deacetylase inhibitory substances preparation method therefor and pharmaceutical composition including same as active ingredient. WO patent WO 2023\/219456 A1. 2023 May 12."},{"key":"e_1_3_3_141_1","unstructured":"Chern J-W Yu C-W Hung P-Y et al. Inventors; Annji pharmaceutical Co. Ltd. assignee. Quinazoline derivatives useful as selective hdac6 inhibitors. WO patent WO 2021\/252475 A1. 2021 Jun 08."},{"key":"e_1_3_3_142_1","unstructured":"Mandegar Mohammad A Patel S Bhatt U et al. Inventors; Tenaya Therapeutics Inc. assignee. 5-fluoronicotinamide derivatives and uses thereof. WO patent WO 2021\/067859 A1. 2020 Oct 02."},{"key":"e_1_3_3_143_1","unstructured":"Hammer K. Inventor; Kancera ab assignee. N-hydroxycarboxamide derivatives useful as inhibitors of mammalian histone deacetylase activity. WO patent WO 2022\/038116 A1. 2021 Aug 17."},{"key":"e_1_3_3_144_1","unstructured":"Vankayalapati H Li Z Lin C et al. Inventors; Baerenkraft Therapeutics LLC assignee. HDAC6 inhibitors and method of their use. WO patent WO 2025\/250930 A1. 2025 May 30."},{"key":"e_1_3_3_145_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12585"},{"key":"e_1_3_3_146_1","unstructured":"Oryzon [Internet]. NBarcelona Spain: Oryzon; [cited 2026 Feb 21]. Available from: https:\/\/www.oryzon.com\/en\/news-events\/news\/positive-preclinical-data-ory-4001-treatment-charcot-marie-tooth-cmt-disease"},{"key":"e_1_3_3_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113281"},{"key":"e_1_3_3_148_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02210"},{"key":"e_1_3_3_149_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.9b00338"},{"key":"e_1_3_3_150_1","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202304545"},{"key":"e_1_3_3_151_1","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2024.110"},{"key":"e_1_3_3_152_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01940"},{"key":"e_1_3_3_153_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01384-0"},{"key":"e_1_3_3_154_1","unstructured":"ALS news Today [Internet]. Pensacola (FL): Bionews; [cited 2026 Feb 21]. Available from: https:\/\/alsnewstoday.com\/news\/otsuka-eikonizo-collaborate-als-therapies-rare-diseases\/"},{"key":"e_1_3_3_155_1","unstructured":"BioSpace [Internet]. Des Moines (IA): BioSpace; [cited 2026 Feb 21]. Available from: https:\/\/www.biospace.com\/press-releases\/eikonizo-therapeutics-announces-investment-by-novo-nordisk-advancing-lead-candidate-ekz-102-toward-clinical-development"},{"key":"e_1_3_3_156_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf380"},{"key":"e_1_3_3_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2015.08.012"},{"key":"e_1_3_3_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102921"},{"key":"e_1_3_3_159_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00519"},{"key":"e_1_3_3_160_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl220159"},{"key":"e_1_3_3_161_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35602-1"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2676080","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543776.2026.2676080","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2676080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:09:44Z","timestamp":1782929384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2676080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":159,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/13543776.2026.2676080"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2676080","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}